Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson"™s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13
https://www.firstwordpharma.com/node/1731315
Advertisement
Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial of SOR-C13 – Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center @MDAndersonNews #pancreaticc…
